Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.

被引：0

作者：

Hodi, F. Stephen

Chiarion-Sileni, Vanna

Lewis, Karl D.

Grob, Jean-Jacques

Rutkowski, Piotr

Lao, Christopher D.

Cowey, Charles Lance

Schadendorf, Dirk

Wagstaff, John

Dummer, Reinhard

Queirolo, Paola

Smylie, Michael

Butler, Marcus O.

Hill, Andrew Graham

Marquez-Rodas, Ivan

Haanen, John B. A. G.

Durani, Piyush

Wang, Peter

Wolchok, Jedd D.

Larkin, James

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] IOV IRCCS, Veneto Inst Oncol, Veneto, Italy

[3] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA

[4] Aix Marseille Univ, CHU Timone, Marseille, France

[5] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[6] Univ Michigan, Michigan Med, Rogel Canc Ctr, Ann Arbor, MI USA

[7] Texas Oncol Baylor Charles Sammons Canc Ctr, Dallas, TX USA

[8] Univ Essen & German Canc Consortium, Essen, Germany

[9] Swansea Univ, Coll Med, Swansea, W Glam, Wales

[10] Univ Spital Zurich, Zurich, Switzerland

[11] IRCCS, European Inst Oncol, IEO, Milan, Italy

[12] Cross Canc Inst, Edmonton, AB, Canada

[13] Univ Hlth Network, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada

[14] Tasman Oncol Res Ltd, Southport, Qld, Australia

[15] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[16] Antonivan Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands

[17] Bristol Myers Squibb, Uxbridge, Middx, England

[18] Bristol Myers Squibb, Princeton, NJ USA

[19] Mem Sloan Kettering Canc Ctr, New York, NY USA

[20] Royal Marsden Hosp, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9522

引用

页数：1

共 50 条

[31] Estimating long-term survivorship in patients with advanced melanoma treated with immune-checkpoint inhibitors: Analyses from the phase III CheckMate 067 trial [J].

Mohr, P. ;

Larkin, J. ;

Paly, V. F. ;

Azocar, A. Remiro ;

Baio, G. ;

Kurt, M. ;

Amadi, A. ;

Rizzo, J. I. ;

Johnson, H. M. ;

Moshyk, A. ;

Kotapati, S. ;

Middleton, M. .

ANNALS OF ONCOLOGY, 2020, 31 :S747-S747

[32] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018) [J].

Hodi, F. S. ;

Chiarion-Sileni, V ;

Gonzalez, R. .

LANCET ONCOLOGY, 2018, 19 (12) :E668-E668

[33] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018) [J].

Hodi, F. S. ;

Chiarion-Sileni, V ;

Gonzalez, R. .

LANCET ONCOLOGY, 2018, 19 (11) :E581-E581

[34] Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067 [J].

Hodi, F. Stephen ;

Chiarion-Sileni, Vanna ;

Gonzalez, Rene ;

Grob, Jean-Jacques ;

Rutkowski, Piotr ;

Lao, Christopher D. ;

Cowey, Charles Lance ;

Schadendorf, Dirk ;

Wagstaff, John ;

Dummer, Reinhard ;

Queirolo, Paola ;

Smylie, Michael ;

Butler, Marcus O. ;

Hill, Andrew Graham ;

Marquez-Rodas, Ivan ;

Ritchings, Corey ;

Sakkal, Leon A. ;

Wang, Peter ;

Wolchok, Jedd D. ;

Larkin, James .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[35] Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study [J].

Tawbi, Hussein A. ;

Forsyth, Peter A. ;

Hodi, F. Stephen ;

Algazi, Alain P. ;

Hamid, Omid ;

Lao, Christopher D. ;

Moschos, Stergios J. ;

Atkins, Michael B. ;

Lewis, Karl ;

Postow, Michael A. ;

Thomas, Reena P. ;

Glaspy, John ;

Jang, Sekwon ;

Khushalani, Nikhil, I ;

Pavlick, Anna C. ;

Ernstoff, Marc S. ;

Reardon, David A. ;

Kudchadkar, Ragini ;

Tarhini, Ahmad ;

Chung, Caroline ;

Ritchings, Corey ;

Durani, Piyush ;

Askelson, Margarita ;

Puzanov, Igor ;

Margolin, Kim A. .

LANCET ONCOLOGY, 2021, 22 (12) :1692-1704

[36] PKPD relationship of ipilimumab plus nivolumab combination in patients with advanced melanoma [J].

Goldwirt, L. ;

Louveau, B. ;

Liv, T. ;

Baroudjian, B. ;

Allayous, C. ;

Da Meda, L. ;

Delyon, J. ;

Sauvageon, H. ;

Lebbe, C. ;

Mourah, S. .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 :38-38

[37] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040. [J].

El-Khoueiry, Anthony B. ;

Yau, Thomas ;

Kang, Yoon-Koo ;

Kim, Tae-You ;

Santoro, Armando ;

Sangro, Bruno ;

Melero, Ignacio ;

Kudo, Masatoshi ;

Hou Ming-Mo ;

Matilla, Ana ;

Tovoli, Francesco ;

Knox, Jennifer J. ;

He, Aiwu Ruth ;

El-Rayes, Bassel F. ;

Acosta-Rivera, Mirelis ;

Lim, Ho Yeong ;

Memaj, Arteid ;

Sama, Ashwin Reddy ;

Hsu, Chiun .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

[38] Long-Term Survival in Patients With Advanced Melanoma [J].

van Not, Olivier J. ;

van den Eertwegh, Alfons J. M. ;

Jalving, Hilde ;

Bloem, Manja ;

Haanen, John B. ;

van Rijn, Rozemarijn S. ;

Aarts, Maureen J. B. ;

van den Berkmortel, Franchette W. P. J. ;

Blank, Christian U. ;

Boers-Sonderen, Marye J. ;

de Groot J. W. B., Jan Willem ;

Hospers, Geke A. P. ;

Kapiteijn, Ellen ;

Leeneman, Brenda ;

Piersma, D. ;

Stevense-den Boer, Marion ;

van der Veldt, Astrid A. M. ;

Vreugdenhil G., Gerard ;

Wouters, Michel W. J. M. ;

Blokx, Willeke A. M. ;

Suijkerbuijk, Karijn P. M. .

JAMA NETWORK OPEN, 2024, 7 (08) :e2426641

[39] IPILIMUMAB IMPROVES OVERALL SURVIVAL IN PATIENTS WITH PREVIOUSLY TREATED, ADVANCED MELANOMA: LONG-TERM SURVIVAL RESULTS FROM A PHASE III TRIAL [J].

Haanen, J. B. ;

Hodi, F. S. ;

O'Day, S. J. ;

McDermott, D. F. ;

Robert, C. ;

Schadendorf, D. ;

van den Eertwegh, A. J. ;

Chen, T. ;

Hoos, A. ;

Urba, W. J. .

ANNALS OF ONCOLOGY, 2010, 21 :402-402

[40] Efficacy and quality of life outcomes in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase 3 trial (CheckMate 067) [J].

Schadendorf, D. ;

Larkin, J. ;

Chiarion-Sileni, V. ;

Gonzalez, R. ;

Rutkowski, P. ;

Grob, J. -J. ;

Cowey, C. L. ;

Lao, C. ;

Taylor, F. ;

Sabater, J. ;

Walker, D. ;

Bhore, R. ;

Wolchok, J. ;

Hodi, F. S. .

MELANOMA RESEARCH, 2016, 26 :E4-E4

← 1 2 3 4 5 →